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Abstract
Background: The introduction of Universal Newborn Hearing Screening (UNHS) programs has drastically contributed
to the early diagnosis of hearing loss in children, allowing prompt intervention with significant results on speech and
language development in affected children. UNHS in the Lazio region has been initially deliberated in 2012; however,
the program has been performed on a universal basis only from 2015. The aim of this retrospective study is to present
and discuss the preliminary results of the UNHS program in the Lazio region for the year 2016, highlighting the
strengths and weaknesses of the program.
Methods: Data from screening facilities in the Lazio region for year 2016 were retrospectively analyzed. Data for Level I
centers were supplied by the Lazio regional offices; data for Level II and III centers were provided by units that
participated to the study.
Results: During 2016, a total of 44,805 babies were born in the Lazio region. First stage screening was performed on
41,821 children in 37 different birth centers, with a coverage rate of 93.3%. Of these, 38.977 (93.2%) obtained a “pass”
response; children with a “refer” result in at least one ear were 2844 (6.8%). Data from Level II facilities are incomplete
due to missing reporting, one of the key issues in Lazio UNHS. Third stage evaluation was performed on 365 children
in the three level III centers of the region, allowing identification of 70 children with unilateral (40%) or bilateral (60%)
hearing loss, with a prevalence of 1.6/1000.
Conclusions: The analysis of 2016 UNHS in the Lazio region allowed identification of several strengths and weaknesses
of the initial phase of the program. The strengths include a correct spread and monitoring of UNHS among Level I
facilities, with an adequate coverage rate, and the proper execution of audiological monitoring and diagnosis among
Level III facilities. Weakness, instead, mainly consisted in lack of an efficient and automated central process for
collecting, monitoring and reporting of data and information.
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Background
Hearing loss is one of the most common defects at birth
occurring in about 1.4 babies per 1000 newborns [1, 2].
Hearing impairment can affect a child’s ability to develop
speech, language and social skills [3]; a late diagnosis can
severely impact on the future life of the child with serious
disability and related high costs [4–6]. A recent study in
the Italian population estimated that the lifetime mean
cost for a subject with profound pre-lingual deafness is
around €700.000 [7].
The early diagnosis and intervention in children with
hearing loss at < 6 months of age leads to significantly
better outcomes for speech and language development
compared to non-treated children [8, 9]. Early diagnosis
is based on Universal Newborn Hearing Screening
(UNHS) programs; intervention relies on the use of
hearing aids and cochlear implants [10]. It has been
largely demonstrated that UNHS is the only effective
way to evaluate the largest portion of population; when
neonatal hearing screening is restricted to high risk
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groups, hearing impairment remains undiagnosed in 30–
50% of infants [10–15]. Furthermore, in the absence of a
UNHS program, moderate to severe hearing loss is not
identified before a mean age of two years and not treated
earlier than 40 months, while mild hearing impairment
is identified even later, sometimes at school age [16].
Several Italian regions have introduced UNHS dur-
ing the last decade, with different results and method-
ologies. In 2017, the Italian Ministry of Health
introduced UNHS among the Essential Levels of Assist-
ance (ELA). Lazio is a region in central Italy with an area
of about 18,000 km2, a population of about six million in-
habitants and 50.000 newborns every year. In the Lazio re-
gion, UNHS has been introduced in 2012 with Regional
Council Resolution n. 115/2012 “Linea d'azione screening
uditivo neonatale universale. Programma di attivazione e
messa a regime”, a document based on the national and
international guidelines [14, 17]. However, UNHS has
been performed regularly on a universal basis only from
2015. A graphical representation of the recommended al-
gorithm for Universal Newborn Hearing Screening in the
Lazio region is shown in Fig. 1.
The aim of this retrospective study is to present and
discuss the results of the 2016 UNHS program in the
Lazio region, highlighting the main strengths and weak-
nesses of the initial phase of the program.
Methods
Operative and geographical organization
UNHS was executed in all birth centers and neonatal in-
tensive care units (NICU) of the region, homogenously
distributed in the territory. Screening facilities, defined by
the regional government in 2012 according to inter-
national guidelines, were divided into three different levels:
– Level I: includes most of birth centers and NICU,
that can execute Transient Evoked Otoacoustic
Emissions (TEOAE) only. TEOAE testing can be
executed by trained nursing personnel,
neonatologists and audiometrists. In the Lazio
region, there are 37 Level I facilities. The original
regional plan included 44 Level I centers; however,
seven smaller centers were subsequently merged.
– Level II: these facilities, mainly available in middle
and large hospitals, execute TEOAE and Automated
Auditory Brainstem Responses (A-ABR). Tests can
be executed by specifically trained personnel
including pediatric nurses, audiometrists,
pediatricians, audiologists, otolaryngologists. In the
Lazio region, there are 11 Level II facilities.
– Level III: Level III centers, also named “reference
centers”, can perform the whole clinical and
audiological evaluation in children, including testing
clinical TEOAE, Distortion Product Otoacoustic
Emissions (DPOAE) and ABR, and lead to a
complete diagnosis of hearing loss and the activation
of the habilitation. In the Lazio region there are
three Level III centers: the Policlinico Umberto I
Hospital, the Agostino Gemelli Hospital, and the
Bambino Gesù Pediatric Hospital.
Detailed data on facilities included in the UNHS in the
Lazio region, and the corresponding Level III center are
outlined in Table 1.
Screening protocol
UNHS should be performed in all newborns within 72 h
after birth before discharge. Screening operative protocol
is divided into three stages.
1. First Stage: initial screening performed on all
newborns in both ears using TEOAE by trained
personnel. TEOAE testing should be performed in a
quiet environment when babies are asleep or
feeding. In the case of a bilateral “pass” response,
the screening is considered completed. In the case of a
“refer” response in one or both ears, it is recommended
to repeat the test before discharge. Newborns with a
“refer” at this first stage evaluation are addressed to
second stage evaluation within 15 days.
2. Second Stage: includes children that do not pass
first stage screening in at least one ear and babies
with a family history of sensorineural hearing loss
or pregnancy or auditory neuropathy risk factors,
according to the Joint Committee on Infant
Hearing (JCIH) 2007, and is executed using A-ABR.
Intrauterine risk factors include maternal infections,
such as Toxoplasmosis, Syphilis, HIV, Hepatitis B,
Rubella, Citomegalovirus, Herpes Simplex during
pregnancy or delivery; admission to a NICU greater
than five days; prematurity (< 37 weeks); exposure
to ototoxic medications such as gentamycin,
tobramycin and furosemide; hyperbilirubinemia that
requires transfusion; syndromes associated with
hearing impairment such as Pendred, Usher,
Waardenburg, Neurofibromatosis; and craniofacial
anomalies, including those involving the pinna, ear
canal, ear tags, ear pits, and temporal bone
anomalies (Table 2). All babies must be tested
within the first month of life. In case of a bilateral
“pass” response at A-ABR, the screening is
considered completed. However, it is recommended
that babies with known risk factors are monitored
with TEOAE, ABR, acoustic immittance testing at
regular intervals every six months for the first three
years, then every twelve months for the following
three years to identify children with late or
progressive hearing loss.
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3. Third Stage (clinical audiological evaluation):
includes children that fail second stage testing in
one or both ears. It is executed by level III
facilities by means of case history, otoscopy,
clinical TEOAE and/or DPOAE, ABR recording
and impedance under supervision of experienced
otolaryngologists or audiologists. All babies must
be tested within the third month of life and
should begin a prosthetic and rehabilitation
treatment within six months of age.
Data collection
The following data for each Level I facility were pro-
vided by regional offices: number of children born
alive; number of children tested; number of children
with a “pass” response; number of children with a
“refer” response. Such data were digitally tracked and
transmitted by Level I facilities to the monitoring of-
fices of the Lazio region.
Data from Level II facilities were provided only by four
centers: Policlinico Umberto I, Policlinico Gemelli, Ospedale
San Camillo Forlanini, Ospedale Pediatrico Bambino
Gesù upon request. Data included: number of children
referred from Level I facilities, although the referring
center was not specified; number of children tested;
number of children with a “pass” response; number of
children with a “refer” response.
Complete data were provided from individual regis-
tries of the three Level III centers of the Lazio region:
Policlinico Umberto I, Policlinico Gemelli, Ospedale
Pediatrico Bambino Gesù. Data included: number of
children referred to Level III centers; number of children
tested; number of children with unilateral/bilateral hearing
loss; degree of hearing loss (mild/moderate; severe/pro-
found). No information was provided on risk factors of
babies included in the screening protocol.
Results
During 2016, a total of 44,805 babies were born in the
Lazio region. First stage screening was performed on
41,821 in 37 different birth centers. They included 26
public hospitals and 11 private hospitals and clinics.
Overall coverage rate was 93.3%. Territory distribution
was as follows: 25 birth centers were in central Lazio
(67.6%); eight in southern Lazio (21.6%) and four in
northern Lazio (10.8%). Among birth centers in cen-
tral Lazio, 21 (84%) were in the city of Rome. When
first stage screening was not possible in a birth center,
children were referred to other level I or II centers.
Children that obtained a “pass” response at first stage
screening were 38,977 (93.2%); children with a “refer”
result in at least one ear were 2844 (6.8%). Detailed
data on first stage screening performed during 2016 in
the Lazio region are shown in Table 3.
Incomplete data reporting from Level II facilities did
not allow a consistent analysis of second stage
screening. Data were received only from four centers
(36.4%), in which second stage screening was per-
formed on 1175 children; among these children, 49
(4.2%) had own or maternal specific risk factors. One
hundred-twenty-five children (10.6%) failed second
Fig. 1 Graphical representation of the recommended algorithm for Universal Newborn Hearing Screening in the Lazio region
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Table 1 Organization of universal newborn hearing screening in the Lazio region
Territory Level I Level II Level III
Rome San Giovanni Calibita – FBF San Giovanni Calibita – FBF Bambino Gesù Hospital
Rome Quisisana
Rome Villa Mafalda
Rome Villa Margherita
Rome Mater Dei
Rome Sant’Eugenio Hospital Sant’Eugenio Hospital Policlinico Umberto I Hospital
Rome San Giovanni Hospital
Rome Vannini Hospital
Rome Fabia Mater
Rome Annunziatella
Rome Policlinico Umberto I Policlinico Umberto I Hospital
Rome Policlinico Casilino
Rome Pertini Hospital
Colleferro Parodi Delfino
Palestrina Coniugi Berardini
Tivoli San Giovanni Evangelista
Rome Grassi Hospital Grassi Hospital
Rome Villa Pia
Rome Città di Roma
Rome San Camillo Hospital San Camillo Hospital
Rome Policlinico Gemelli Policlinico Gemelli Policlinico Gemelli
Rome Santo Spirito Hospital
Rome Santa Famiglia
Rome Cristo Re
Rome San Pietro - FBF Bambino Gesù Hospital Bambino Gesù Hospital
Rome Aurelia Hospital
Rome Santa Maria di Leuca
Rome San Filippo Neri
Civitavecchia San Paolo Hospital
Anzio P.O. Anzio Nettuno
Albano Laziale P.O. Albano
Marino San Giuseppe
Velletri Civile Paolo Colombo
Latina P.O. Latina Nord P.O. Latina Nord
Terracina P.O. Latina Centro
Formia P.O. Latina Sud
Aprilia Città di Aprilia
Tarquinia Civile di Tarquinia Belcolle Hospital Policlinico Gemelli
Viterbo Belcolle Hospital
Rieti P.O. Rieti P.O. Rieti
Frosinone Spaziani Hospital Spaziani Hospital
Alatri San Benedetto
Sora Santissima Trinità
Cassino Santa Scolastica
Names and distribution of Level I, II and III facilities in the Lazio region
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stage screening and were referred to Level III centers
for clinical diagnosis of hearing loss.
Third stage evaluation was performed on 365 chil-
dren in the Level III centers of the Lazio region. They
included children that failed second stage testing and
children that were referred by other hospitals for risk
factors. Data are summarized in Table 4.
– Policlinico Umberto I: 44 children were referred for
clinical hearing evaluation; 33 were children that did
not pass second stage screening (21 in the same
center, 11 in a different hospital), 12 were referred
for risk factors. Two children dropped out and could
not be tested. Of tested children, 18 had normal
clinical ABR in both ears and were considered
having normal hearing; 24 were diagnosed with
clinical hearing loss (13 unilateral, 11 bilateral), and
they included four children with risk factors.
Children with bilateral hearing impairment had
profound hearing loss in two cases, severe in three
cases, and moderate in six cases; children with
unilateral hearing impairment had profound hearing
loss in three cases, severe in two cases, moderate in
five cases, and mild hearing loss in three cases.
– Policlinico Gemelli: 114 children were referred to this
center for clinical hearing evaluation; 39 failing second
stage screening (32 from same center, 7 from a
different center) and 75 for risk factors. Sixty-six
children dropped out and could not be tested.
Forty-eight children underwent clinical ABR; 31 had
normal hearing and 17 were diagnosed with clinical
hearing loss (nine unilateral, eight bilateral). All chil-
dren with bilateral hearing impairment had a moder-
ate hearing loss in both ears (one had moderate
hearing loss in one ear and mild in the other); chil-
dren with
unilateral hearing impairment had a profound hearing
loss in two cases, severe in one case, mild in six cases.
– Ospedale Pediatrico Bambino Gesù: 207 children
were tested with clinical ABR. Of these, 29 were
diagnosed with unilateral (6/29) or bilateral (23/29)
hearing loss. Children with bilateral hearing
impairment had profound hearing loss in 11 cases,
severe in four cases, and moderate in seven cases;
children with unilateral hearing impairment had
profound hearing loss in one case, severe hearing
loss in two cases, and moderate in three cases.
The total number of children diagnosed with unilateral
or bilateral hearing impairment during 2016 by Level III
centers in the Lazio region was 70, with a prevalence of
1.6/1000. Children with a diagnosis of unilateral hearing
loss were 28 (0.62/1000), while children with bilateral
hearing impairment were 42 (0.93/1000). Incomplete
data reporting does not allow calculating specific data
for well born babies and babies with risk factor.
Discussion
This is the first study that analyses the results of the
UNHS in the Lazio region. Previous studies in other
Italian regions include Liguria [18], Umbria [19], Tuscany
[20], Campania [21] and Sicily [22], while other reports fo-
cused on specific cities or hospitals, such as the Ferrara
[23], Pisa [24], Parma [25], Milan [26] and Siena experi-
ences [27]. Our study shows a coverage rate in the Lazio
region in 2016 of 93.3%, which is close to the recommen-
dations by the JCIH guidelines that require a minimum
coverage rate for the newborn population of 95% and a
percentage of false positive < 3% [14]. The coverage rate of
the Lazio region is also in line with national averages, that
have consistently increased over the past years. In the
past, a study from Bubbico et al. [28] investigated the evo-
lution of the coverage rate of UNHS in several Italian re-
gions from 2003 to 2011, showing a progressive increase
of coverage that reached in 2011 a national average of
78.3%; coverage exceeded 95% in 12/20 regions especially
in the North West and North East regions, while some
areas such as the main islands still showed a limited diffu-
sion of hearing screening programs. In 2017 the Italian
Ministry of Health introduced UNHS among the ELA;
this will allow a further increase of the coverage rate in
the upcoming years.
UNHS in the Lazio region allowed identification of 70
children diagnosed with unilateral (40%) or bilateral (60%)
hearing loss during 2016, with a prevalence of 1.6/1000.
Table 2 Audiological risk factors
Audiological risk factor— JCIH
Family history of hereditary childhood sensorineural hearing loss
In-utero infection (e.g., rubella, cytomegalovirus, syphilis, toxoplasmosis,
herpes) Craniofacial anomalies
Low birth weight (b1500 g or 3.3 lb)
Hyperbilirubinemia at levels requiring exchange transfusion
Bacterial meningitis
Exposure to ototoxic medications
Mechanical ventilation lasting 5 days or longer
Stigmata or other findings associated with a syndrome known to
include a sensorineural and/or conductive hearing loss
Apgar scores of 0–4 at 1 min or 0–6 at 5 min
Admission to the Neonatal Intensive Care Unit (NICU)
Parent/caregiver concern regarding hearing, speech, language, and/or
developmental delay
Head trauma associated with loss of consciousness or skull fracture
Recurrent or persistent otitis media with effusion lasting for at least
3 months
Audiological risk factor according to the Joint Committee on Infant
Hearing (JCIH)
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This result is close to estimates in the United States that
range from 1 to 3 per 1000 newborns [1] and to that of
other Italian studies [18, 20, 24, 25, 27]. A study on preva-
lence of prelingual deafness in Italy published in 2007
showed 40,887 cases of prelingual sensorineural hearing
impairment ≥60 dB, with a prevalence in the Italian
population of 0.72 per 1000 inhabitants [29]. These results
could therefore confirm the validity of the screening
organizational model developed in the Lazio region.
A significant number of children with a clinical diagno-
sis of hearing impairment had unilateral hearing loss, a
condition that is often underestimated and untreated, in
Table 3 First stage screening results
BIRTH CENTERS BORN ALIVE TESTED % TESTED PASS REFER % REFER
San Giovanni FBF 3643 3580 98,27% 3552 28 0,78%
Quisisana 84 41 48,81% 41 0 0,00%
Villa Mafalda 30 5 16,67% – – –
Villa Margherita 132 94 71,21% 94 0 0,00%
San Giovanni Addolorata 337 337 100,00% 289 48 14,24%
Sant’Eugenio 1107 1102 99,55% 1018 84 7,62%
M.G. Vannini 300 291 97,00% 279 12 4,12%
Fabia Mater 1730 622 35,95% 600 22 3,54%
Pol. Umberto I 1641 1551 94,52% 1307 244 15,73%
Pol. Casilino 2746 2710 98,69% 2613 97 3,58%
Sandro Pertini 1152 1075 93,32% 1045 30 2,79%
Con. Bernardini (Palestrina) 705 697 98,87% 670 27 3,87%
San Giovanni E. (Tivoli) 678 666 98,23% 605 61 9,16%
GB. Grassi 1711 1700 99,36% 1680 20 1,18%
Città di Roma 1278 1269 99,30% 1264 5 0,39%
San Camillo Forlanini 2580 2645 102,52% 2352 293 11,08%
S. Spirito 643 633 98,44% 622 11 1,74%
Santa Famiglia 1833 1829 99,78% 1815 14 0,77%
Cristo Re 1929 1316 68,22% 1272 44 3,34%
Policlinico Gemelli 3697 3697 100,00% 3323 374 10,12%
San Filippo Neri 951 933 98,11% 820 113 12,11%
Ospedale San Pietro FBF 4545 3954 87,00% 3954 604 15,28%
Aurelia Hospital 444 424 95,50% 414 10 2,36%
S Maria di Leuca 94 85 90,43% 85 0 0,00%
O. S. Paolo 427 427 100,00% 425 2 0,47%
P.O. Anzio Nettuno 545 532 97,61% 527 5 0,94%
P.O. Albano Genzano 850 809 95,18% 809 0 0,00%
P.O. Paolo Colombo 530 516 97,36% 512 4 0,78%
P.O. Latina Nord 1705 1911 112,08% 1909 1 0,05%
P.O. Latina Centro 836 836 100,00% 835 1 0,12%
P.O. Latina Sud 625 625 100,00% 623 2 0,32%
Città di Aprilia 580 400 68,97% 398 2 0,50%
Belcolle Viterbo 1234 1234 100,00% 930 304 24,64%
San Camillo de Lellis 526 418 79,47% 413 5 1,20%
Fabrizio Spaziani FR 1352 1352 100,00% 1067 285 21,08%
Santissimia Trinità FR 910 491 53,96% 486 5 1,02%
Santa Scolastica 695 703 101,15% 569 134 19,06%
Total 44,805 41,510 92.65% 39,217 2891 7.37%
First stage screening in the birth centers of the Lazio region in 2016
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part because of lack of awareness of possible conse-
quences [30–33]. Usually, children with unilateral hearing
loss enter a protocol of subsequent follow-up to monitor a
possible evolution into bilateral forms. Also, screening
may miss mild permanent hearing loss misdiagnosing it
with a transitory conductive form. Due to the high per-
centage of unilateral hearing loss, it is therefore important
to take this condition into account when evaluating and,
especially, predisposing an intervention plan.
Our study highlighted several difficulties in the current
procedures and methodologies of the UNHS program per-
formed in the Lazio region that may also apply to other
realities. One of the main issues is the incomplete data
collection from Level II facilities due the absence of a
functioning reporting network between these facilities and
Level I and III structures, further worsened by the lack of
coordination from central regional offices. Our analysis is
based on data from about 35% of Level II centers; this did
not allow a consistent analysis of second stage screening
with potential serious consequences not only on UNHS
monitoring, but also on the effectiveness of the program
with increased number of lost to follow-up (LFU) children
and delayed diagnosis of hearing loss. Furthermore, the
lack of data sharing from Level II facilities does not allow
differentiating between well born children with a “refer”
response at first stage and children with risk factors that
are sent directly to second stage screening. Data from
Level I facilities are transmitted and tracked by the moni-
toring office at the Lazio region allowing correct reporting
of coverage. It would be auspicial to also extend such
monitoring activity to Level II and Level III facilities, as
already in place in some other Italian regions [18, 19].
There are some additional important data that are
missing from this study. The first is the number of
babies with risk factors. A study from Ghirri et al. [24]
reported a prevalence of 6.1% in the Pisa hospital; Molini
[19] reported a prevalence of 3.8% in Umbria. Data from
the literature describe a prevalence between 3% and 5%
of neonatal risk factors for hearing loss in the general
population. In the Lazio region, the number of children
with neonatal or maternal risk factors was not tracked at
a central level, and therefore this data was not included
in the present study. Secondarily, but not less important,
age of patients included in third stage evaluation is un-
known. Data for this stage were received directly from
Level III facilities and were collected using different
methodologies. Taken into account that all patients in
Level III facilities followed the entire screening protocol,
it could be assumed that diagnoses were performed
within the first year of life. However, missing age data
did not allow us to exactly evaluate the mean age of
diagnosis. Moreover, no information about the beginning
of audiological treatment was received.
Data about auditory neuropathy spectrum disorders
(ANSD) were not available. In children with ANSD, the
integrity of outer hair cells results in a “pass” response at
TEOAE and therefore auditory dysfunction may remain
undiagnosed at first stage evaluation [34–36]. To reduce
the risk of undiagnosed ANSD, it is recommended to initi-
ate auditory monitoring in babies with risk factors and in-
struct families of children who pass first stage to perform
a further audiological evaluation if they notice abnormal-
ities of auditory behavior in their children. Data from
ANSD have not been collected in the present study;
however, prevalence and natural history of ANSD is still
largely unknown and possible revision of current screen-
ing protocols may be warranted as more information on
these disorders become available [27].
Table 4 Third stage screening results
Policlinico Umberto I Policlinico Gemelli Bambino Gesù
Included (RF) 44 (12) 114 (75) 207
Tested (%) 42 (95.4) 48 (42.1) 207 (100)
Normal Hearing (%) 18 (42.9) 31 (64.6) 178 (86)
Hearing Loss (%) [RF] 24 (57.1) [4] 17 (35.4) 29 (14)
Unilateral (%) 13 (54.2) 9 (52.9) 6 (20.7)
Mild (%) 3 (23.1) 6 (66.7) -- (−)
Moderate (%) 5 (38.5) -- (−) 3 (50)
Severe (%) 2 (15.4) 1 (11.1) 2 (30)
Profound (%) 3 (23.1) 2 (22.2) 1 (20)
Bilateral (%) 11 (45.8) 8 (47.1) 23 (79.3)
Mild (%) -- (−) -- (−) -- (−)
Moderate (%) 6 (54.5) 8 (100) 7 (30.4)
Severe (%) 3 (27.3) -- (−) 4 (17.4)
Profound (%) 2 (18.2) -- (−) 11 (47.8)
Third stage screening performed in Level III centers of the Lazio region in 2016. RF: Risk Factors
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LFU babies (newborns who fail the initial testing and
are lost during follow-up) represent a common and alarm-
ing problem in UNHS [37–39]. In our study, data from
Level III facilities showed an LFU rate < 5% for 2 centers,
and a very high rate for the third center (Policlinico
Gemelli). The data from the third center could be ex-
plained by regional or national mobility of these patients
and may be biased by the unexpectedly very high number
of babies with risk factors reported by that center. Instead,
data about LFU patients between first and second and
between second and third stages are not available. The
collection of this data is necessary and important to moni-
tor and actuate intervention strategies aimed to limit the
number of LFU patients, such as targeted training to the
personnel involved in screening procedures and
appropriate education about UNHS and the risk factors of
undiagnosed hearing impairment to pediatricians, neona-
tologists and gynecologists, and families. Better communi-
cation between centers and central regional offices is of
utmost importance to limit LFU patients and increase
effectiveness of UNHS.
Last, a noteworthy problem of UNHS that was en-
countered in our analysis is the heterogeneity between
Level I centers in performing an A-TEOAE retest on
refer children before addressing them to Level II centers.
The utility of this retest has been demonstrated in sev-
eral studies, allowing a drastic reduction of false positives
and, therefore, of the workload for Level II and III facilities
[24, 40]. However, in the Lazio region not all facilities per-
form such retest; this should be corrected and could ex-
plain the high variability of refer patients between Level I
centers that ranged between 0% of some birth centers to
over 20% of others (see Table 3).
Conclusions
A correct and early diagnosis of hearing loss is mandatory
to prevent its linguistic, developmental and educational
consequences; the spread of UNHS programs is the
optimal solution to reach this goal. The implementation of
a UNHS program at a regional level requires consistent
organizational efforts and is characterized by intercon-
nected processes, activities and reporting. The analysis of
2016 UNHS in the Lazio region – although preliminary -
allowed identification of several strengths and weaknesses
of the program. The strengths included a correct spread
and monitoring of UNHS among Level I facilities, with an
adequate coverage rate, and the proper execution of audio-
logical monitoring and diagnosis among Level III facilities.
Weakness, instead, mainly consisted in lack of an efficient
and automated central process for collecting, monitoring
and reporting of data and information. Such lack may
affect the overall effectiveness of the screening program; in
fact, although single participants involved in the UNHS
program appeared to be fully responsible for their activity,
the central coordination by the Lazio regional offices only
included the first stage of screening and is currently not
extended to Level II and III facilities. It would be auspicial
to increase effectiveness of the screening program and to
favor a constant bidirectional flow of data between centers,
stages and central monitoring offices.
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